Spectral Medical Inc
TSX:EDT
Intrinsic Value
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. [ Read More ]
The intrinsic value of one
EDT
stock under the Base Case scenario is
0.029
CAD.
Compared to the current market price of 0.425 CAD,
Spectral Medical Inc
is
Overvalued by 93%.
Spectral Medical Inc's market capitalization is 118.4m CAD.
EDT stock price is 0.425 CAD.
EDT stock (0.029 CAD) is 93% less than its price (0.425 CAD).
EDT. Open DCF Valuation
EDT stock (0.029 CAD) is 93% less than its price (0.425 CAD). Open Relative Valuation
EDT has upside potential of 284% compared to the average analyst price target.
Open Wall St Estimates
EDT's Revenue has dropped by 4% over the past 12 months.
EDT's Revenue has been falling by 9% per year for the last 3 years.
EDT has positive Net Debt. This means that the company has more debt (8m CAD) than cash and short-term investments (3m CAD).
EDT's ROE (Return on Equity) has significantly increased in the last 3 years from -29 320% to 164%.
EDT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 612% to 16 647%.
EDT has negative Operating Income for the last twelve months.
EDT has negative Net Income for the last twelve months.
EDT's ROE (Return on Equity) for the past 12 months is very high and is equal to 164%.
EDT's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 16 647%.
EDT has positive Gross Profit for the last twelve months.
EDT's short-term liabilties (10m CAD) exceed its short-term assets (4m CAD).
EDT has negative Free Cash Flow for the last twelve months.
EDT's long-term liabilties (22m CAD) exceed its long-term assets (5m CAD).
EDT has negative three-year average ROE (Return on Equity): -2 445%. The company is not efficient at transforming stockholders' equity into net income.
EDT has very high three-year average ROIC (Return on Invested Capital): 438%. The company is very efficient at using invested capital to generate operating income.
EDT's D/E (Debt to Equity) is very low and is equal to -0.49.
EDT's Altman Z-Score is very low and is equal to -38.97.
Valuation Backtest
Spectral Medical Inc
Run backtest to discover the historical profit from buying and selling
EDT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Spectral Medical Inc
Balance Sheet Decomposition
Spectral Medical Inc
| Current Assets | 4.1m |
| Cash & Short-Term Investments | 3m |
| Receivables | 186k |
| Other Current Assets | 987k |
| Non-Current Assets | 1.1m |
| PP&E | 893k |
| Intangibles | 193k |
| Current Liabilities | 10.2m |
| Accounts Payable | 2.8m |
| Other Current Liabilities | 7.4m |
| Non-Current Liabilities | 11.5m |
| Long-Term Debt | 8.2m |
| Other Non-Current Liabilities | 3.3m |
Earnings Waterfall
Spectral Medical Inc
|
Revenue
|
1.6m
CAD
|
|
Cost of Revenue
|
-936k
CAD
|
|
Gross Profit
|
662k
CAD
|
|
Operating Expenses
|
-12.4m
CAD
|
|
Operating Income
|
-11.7m
CAD
|
|
Other Expenses
|
-3.9m
CAD
|
|
Net Income
|
-15.7m
CAD
|
Free Cash Flow Analysis
Spectral Medical Inc
EDT Profitability Score
Profitability Due Diligence
Spectral Medical Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Spectral Medical Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
EDT Solvency Score
Solvency Due Diligence
Spectral Medical Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Spectral Medical Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EDT Price Targets Summary
Spectral Medical Inc
According to Wall Street analysts, the average 1-year price target for
EDT
is 1.632 CAD
with a low forecast of 1.616 CAD and a high forecast of 1.68 CAD.
Shareholder Return
EDT Price
Spectral Medical Inc
| Average Annual Return | 19.07% |
| Standard Deviation of Annual Returns | 77.39% |
| Max Drawdown | -74% |
| Market Capitalization | 118.4m CAD |
| Shares Outstanding | 278 576 261 |
| Percentage of Shares Shorted | 0.13% |
Company Profile
Spectral Medical Inc
Country
Industry
Market Cap
Dividend Yield
Description
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.
Contact
IPO
Employees
Officers
The intrinsic value of one
EDT
stock under the Base Case scenario is
0.029
CAD.
Compared to the current market price of 0.425 CAD,
Spectral Medical Inc
is
Overvalued by 93%.
You don't have any saved screeners yet
